department
of
health
and
human
services
food
and
drug
administration
21
cfr
part
74
[
docket
no
.
92c0294
]
listing
of
color
additives
subject
to
certification
;
dampc
green
no
.
5
<
agency
>
agency
:
food
and
drug
administration
,
hhs
.
<
agency
>
<
action
>
action
:
final
rule
.
<
action
>
<
summary
>
summary
:
the
food
and
drug
administration
(
fda
)
is
amending
the
color
additive
regulations
to
provide
for
the
safe
use
of
dampc
green
no
.
5
for
coloring
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
this
action
is
in
response
to
a
petition
filed
by
the
cosmetic
,
toiletry
,
and
fragrance
association
(
ctfa
.
<
summary
>
<
date
>
dates
:
effective
09/12/1994
,
except
as
to
any
provisions
that
may
be
stayed
by
the
filing
of
proper
objections
;
written
objections
and
requests
for
a
hearing
by
09/09/1994
.
<
date
>
<
address
>
addresses
:
submit
written
objections
to
the
dockets
management
branch
(
hfa305
hfa
,
food
and
drug
administration
,
rm
.
123
,
12420
parklawn
dr
,
rockville
,
md
20857
.
<
address
>
<
further
>
for
further
information
contact
:
robert
l
.
martin
,
center
for
food
safety
and
applied
nutrition
(
hfs217
hfs
,
food
and
drug
administration
,
200
c
st
.
sw
,
washington
,
dc
20204
,
2022549519
.
<
further
>
<
supplem
>
supplementary
information
:
i
.
introduction
in
a
notice
published
in
the
federal
register
of
08/11/1992
(
57
fr
35833
,
fda
announced
that
a
color
additive
petition
(
cap
6c0204
)
had
been
filed
by
ctfa
,
1101
17th
st
.
nw
,
suite
300
,
washington
,
dc
20036
.
the
petition
proposed
that
the
color
additive
regulations
for
dampc
green
no
.
5
be
amended
to
provide
for
the
safe
use
of
dampc
green
no
.
5
for
coloring
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
the
petition
was
filed
under
section
706
(
currently
section
721
)
of
the
federal
food
,
drug
,
and
cosmetic
act
(
the
act
)
(
21
usc
.
376
)
(
currently
21
usc
.
379e
.
ii
.
regulatory
history
the
regulatory
history
of
dampc
green
no
.
5
is
summarized
in
a
final
rule
that
was
published
in
the
federal
register
of
06/04/1982
(
47
fr
24278
.
in
that
final
rule
,
fda
permanently
listed
dampc
green
no
.
5
for
use
in
drugs
and
cosmetics
excluding
use
in
the
area
of
the
eye
.
these
actions
were
taken
in
response
to
a
color
additive
petition
(
cap
8c0084
.
iii
.
definitions
section
703s
)
(
21
cfr
703s
)
defines
the
term
`
area
of
the
eye
'
as
`
the
area
enclosed
within
the
circumference
of
the
supraorbital
supra
orbital
ridge
and
the
infraorbital
infra
orbital
ridge
,
including
the
eyebrow
,
the
skin
below
the
eyebrow
,
the
eyelids
and
the
eyelashes
,
and
conjunctival
sac
of
the
eye
,
the
eyeball
,
and
the
soft
areolar
tissue
that
lies
within
the
perimeter
of
the
infraorbital
infra
orbital
ridge
'
21
cfr
705a
)
states
that
`
no
listing
or
certification
of
a
color
additive
shall
be
considered
to
authorize
the
use
of
any
such
color
additive
in
any
article
intended
for
use
in
the
area
of
the
eye
unless
such
listing
or
certification
of
such
color
additive
specifically
provides
for
such
use
'
the
petitioner
has
requested
that
the
uses
for
dampc
green
no
.
5
be
expanded
to
include
drug
and
cosmetic
uses
in
the
area
of
the
eye
.
iv
.
the
color
additive
dampc
green
no
.
5
is
principally
the
disodium
salt
of
22910dihydro910dioxo14anthracenediyldiiminobis5methylbenzenesulfonic
dihydro
acid
]
(
cas
reg
.
no
.
4403901
.
the
manufacture
of
dampc
green
no
.
5
is
accomplished
by
the
sulfonation
of
dampc
green
no
.
6
with
fuming
sulfuric
acid
.
because
dampc
green
no
.
6
is
the
starting
material
in
this
manufacturing
process
,
the
possibility
exists
that
the
chemicals
used
in
the
synthesis
of
dampc
green
no
.
6
may
be
present
in
minor
amounts
in
dampc
green
no
.
5
.
dampc
green
no
.
6
is
formed
by
chemically
reacting
one
molecule
of
quinizarin
with
two
molecules
of
-
toluidine
.
the
significance
of
these
components
is
that
weisburger
et
al
.
have
demonstrated
that
-
toluidine
is
a
carcinogen
in
mice
(
ref
.
1
.
residual
amounts
of
reactants
,
such
as
-
toluidine
and
related
manufacturing
aids
,
are
commonly
found
among
the
constituents
of
many
color
additives
.
the
presence
of
such
constituents
,
however
,
is
not
unique
to
color
additives
.
numerous
contaminants
are
unavoidably
present
in
all
chemical
products
,
even
in
highly
purified
reagent
grade
chemicals
.
although
dampc
green
no
.
5
has
itself
not
been
shown
to
cause
cancer
,
it
does
contain
minor
amounts
of
a
carcinogenic
impurity
,
-
toluidine
.
the
carcinogenicity
of
-
toluidine
was
discussed
in
the
final
rule
,
published
in
the
of
federal
register
06/04/1982
(
47
fr
24278
,
permanently
listing
dampc
green
no
.
5
for
use
in
drugs
and
cosmetics
,
excluding
use
in
the
area
of
the
eye
.
v
.
determination
of
safety
under
section
721b4
)
of
the
act
(
21
usc
.
379eb4
,
the
socalled
so
called
`
general
safety
clause
'
for
color
additives
,
a
color
additive
cannot
be
listed
for
a
particular
use
unless
a
fair
evaluation
of
the
data
available
to
fda
establishes
that
the
color
additive
is
safe
for
that
use
.
fdas
color
additive
regulations
(
703i
)
define
safe
as
`
convincing
evidence
that
establishes
with
a
reasonable
certainty
that
no
harm
will
result
from
the
intended
use
of
the
color
additive
'
the
anticancer
or
delaney
clause
of
the
color
additive
amendments
(
section
721b5b
)
of
the
act
)
provides
that
a
noningested
color
additive
shall
be
deemed
unsafe
and
shall
not
be
listed
if
,
after
tests
that
are
appropriate
for
evaluating
the
safety
of
the
additive
for
such
use
,
it
is
found
to
induce
cancer
in
man
or
animal
.
importantly
,
however
,
the
delaney
clause
applies
to
the
additive
itself
and
not
to
constituents
of
the
additive
.
that
is
,
where
an
additive
itself
has
not
been
shown
to
cause
cancer
,
but
contains
a
carcinogenic
impurity
,
the
additive
is
properly
evaluated
under
the
general
safety
clause
using
risk
assessment
procedures
to
determine
whether
there
is
a
reasonable
certainty
that
no
harm
will
result
from
the
proposed
use
of
the
additive
(
(
scott
v
.
fda
,
,
728
f
2d
322
(
6th
cir
.
1984
.
vi
.
safety
of
the
petitioned
use
of
the
additive
fda
estimates
from
the
data
submitted
and
other
relevant
information
that
the
exposure
to
dampc
green
no
.
5
from
its
use
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
,
is
0
56
milligrams
per
person
per
day
(
mg
p
d
,
based
upon
a
maximum
frequency
of
application
and
maximum
quantity
applied
.
fda
does
not
ordinarily
consider
chronic
toxicological
testing
to
be
necessary
to
determine
the
safety
of
an
additive
whose
use
will
result
in
such
low
exposure
levels
(
ref
.
2
,
and
the
agency
has
not
required
such
testing
here
.
although
the
agency
does
not
normally
require
such
testing
,
chronic
studies
supporting
current
listings
for
the
use
of
dampc
green
no
.
5
are
available
in
the
agencys
files
,
and
fdas
safety
evaluation
for
the
proposed
use
of
the
color
additive
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
included
a
consideration
of
these
studies
.
twoyear
two
year
carcinogenicity
studies
of
dampc
green
no
.
5
showed
no
indication
of
carcinogenicity
.
fda
has
evaluated
the
safety
of
this
additive
under
the
general
safety
clause
,
considering
all
available
data
.
the
agency
has
used
risk
assessment
procedures
to
estimate
the
upperbound
upper
bound
limit
of
risk
presented
by
-
toluidine
,
the
carcinogenic
chemical
that
may
be
present
as
an
impurity
in
the
additive
.
the
risk
evaluation
of
this
chemical
has
two
aspects
:
(
1
)
assessment
of
the
exposure
to
the
impurity
from
the
proposed
use
of
the
additive
,
and
(
2
)
extrapolation
of
the
risk
observed
in
the
animal
bioassays
to
the
conditions
of
probable
exposure
to
humans
.
fda
estimates
that
the
maximum
total
lifetime
exposure
to
-
toluidine
that
will
result
from
the
use
of
dampc
green
no
.
5
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
that
complies
with
the
applicable
specifications
is
84
nanograms
(
ng
p
d
.
this
exposure
estimate
was
based
on
the
use
of
this
color
additive
in
eyebrow
pencil
,
eyeliner
,
eye
shadow
,
eye
lotion
,
eye
makeup
remover
,
mascara
,
eye
cream
,
eye
shadow
base
,
and
eye
stick
.
the
agency
used
data
reported
by
the
national
cancer
institute
which
demonstrated
that
-
toluidine
was
carcinogenic
for
male
and
female
charles
river
cd1
(
ham
icr
derived
)
mice
,
causing
an
increased
incidence
of
hepatomas
(
liver
tumors
)
(
ref
.
1
)
to
estimate
the
upperbound
upper
bound
limit
of
lifetime
human
risk
from
exposure
to
this
chemical
stemming
from
the
proposed
use
of
dampc
green
no
.
5
as
a
color
additive
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
(
ref
.
3
.
based
on
a
potential
exposure
of
84
ng
p
d
,
fda
estimates
that
the
upperbound
upper
bound
limits
of
individual
lifetime
risk
from
the
potential
exposure
to
-
toluidine
from
the
proposed
use
of
dampc
green
no
.
5
as
a
color
additive
in
eye
area
drugs
and
cosmetics
is
2
x
10
-
9
or
2
in
1
billion
(
ref
.
4
.
moreover
,
fda
points
out
that
in
an
earlier
determination
of
the
risk
from
exposure
to
-
toluidine
from
all
other
uses
of
dampc
green
no
.
5
,
the
agency
calculated
the
upperbound
upper
bound
limits
of
individual
lifetime
risk
to
be
in
the
1
in
30
million
to
1
in
300
million
range
(
47
fr
24278
.
thus
,
the
use
of
dampc
green
no
.
5
in
eye
area
drugs
and
cosmetics
does
not
increase
this
risk
in
any
way
.
the
agency
also
points
out
that
because
of
the
numerous
conservative
assumptions
used
in
calculating
the
exposure
estimate
,
actual
lifetimeaveraged
lifetime
averaged
individual
exposure
to
-
toluidine
is
expected
to
be
substantially
less
than
the
worstcase
worst
case
exposure
.
therefore
,
the
actual
upperbound
upper
bound
limits
of
risk
would
be
less
than
that
cited
above
.
thus
,
the
agency
concludes
that
there
is
a
reasonable
certainty
of
no
harm
from
exposure
to
-
toluidine
that
might
result
from
the
proposed
use
of
dampc
green
no
.
5
for
coloring
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
in
its
evaluation
of
the
safety
of
the
proposed
use
of
the
subject
additive
,
fda
has
also
considered
other
safety
data
submitted
previously
to
support
current
listings
for
the
use
of
dampc
green
no
.
5
.
these
toxicity
studies
of
dampc
green
no
.
5
,
involving
dogs
,
rats
,
and
mice
,
included
acute
oral
toxicity
studies
,
subchronic
studies
,
and
chronic
toxicity
studies
in
which
animals
were
exposed
to
the
color
additive
through
diet
and
skin
applications
,
and
reproductive
toxicity
studies
.
these
studies
did
not
produce
any
evidence
that
dampc
green
no
.
5
would
be
unsafe
for
the
petitioned
uses
.
in
addition
,
fda
evaluated
the
ocular
toxicity
studies
that
the
petitioner
provided
to
support
the
proposed
use
of
dampc
green
no
.
5
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
almost
all
of
the
animals
were
free
of
signs
of
ocular
irritation
.
the
effects
noted
in
most
animals
that
exhibited
irritation
were
slight
conjunctival
redness
or
discharge
.
these
irritations
were
seen
sporadically
in
both
control
and
test
animals
.
based
on
its
review
of
these
studies
,
fda
finds
that
there
were
no
significant
adverse
clinical
findings
in
the
ocular
irritation
studies
.
vii
.
conclusions
a
.
safety
based
upon
the
available
toxicity
data
and
other
relevant
considerations
discussed
above
,
fda
concludes
that
there
is
a
reasonable
certainty
that
no
harm
will
result
from
the
use
of
dampc
green
no
.
5
as
a
color
additive
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
the
agency
also
concludes
on
the
basis
of
available
data
that
the
color
additive
will
perform
its
intended
technical
effect
and
thus
is
suitable
for
the
petitioned
uses
.
the
agency
,
therefore
,
is
amending
§
74
1205
)
and
74
2205
)
of
the
color
additive
regulations
to
provide
for
the
use
of
dampc
green
no
.
5
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
b
.
specifications
dampc
green
no
.
5
is
currently
produced
as
a
certifiable
color
additive
for
use
in
drugs
and
cosmetics
excluding
use
in
the
area
of
the
eye
in
amounts
consistent
with
current
good
manufacturing
practices
in
accordance
with
21
cfr
part
80
.
based
upon
the
low
level
of
exposure
to
-
toluidine
that
results
under
the
current
specifications
for
dampc
green
no
.
5
in
§
74
1205
and
74
2205
(
21
cfr
74
1205
and
74
2205
,
the
agency
concludes
that
the
specifications
listed
in
§
74
1205
are
adequate
to
ensure
the
safe
use
of
this
color
additive
and
to
control
the
amount
of
-
toluidine
that
may
exist
as
an
impurity
in
the
color
additive
when
used
in
drugs
and
cosmetics
intended
for
use
in
the
area
of
the
eye
.
viii
.
inspection
of
documents
in
accordance
with
§
71
15
(
21
cfr
71
15
,
the
petition
and
the
documents
that
fda
considered
and
relied
upon
in
reaching
its
decision
to
approve
the
petition
are
available
for
inspection
at
the
center
for
food
safety
and
applied
nutrition
(
address
above
)
by
appointment
with
the
information
contact
person
listed
above
.
as
provided
in
§
71
15
,
the
agency
will
delete
from
the
documents
any
materials
that
are
not
available
for
public
disclosure
before
making
the
documents
available
for
inspection
.
ix
.
environmental
impact
the
agency
has
carefully
considered
the
potential
environmental
effects
of
this
action
.
fda
has
concluded
that
the
action
will
not
have
a
significant
impact
on
the
human
environment
,
and
that
an
environmental
impact
statement
is
not
required
.
the
agencys
finding
of
no
significant
impact
and
the
evidence
supporting
that
finding
,
contained
in
an
environmental
assessment
,
may
be
seen
in
the
dockets
management
branch
(
address
above
)
between
9
am
.
and
4
pm
,
monday
through
friday
.
x
.
objections
any
person
who
will
be
adversely
affected
by
this
regulation
may
at
any
time
on
or
before
09/09/1994
,
file
with
the
dockets
management
branch
(
address
above
)
written
objections
thereto
.
each
objection
shall
be
separately
numbered
,
and
each
numbered
objection
shall
specify
with
particularity
the
provisions
of
the
regulation
to
which
objection
is
made
and
the
grounds
for
the
objection
.
each
numbered
objection
on
which
a
hearing
is
requested
shall
specifically
so
state
.
failure
to
request
a
hearing
for
any
particular
objection
shall
constitute
a
waiver
of
the
right
to
a
hearing
on
that
objection
.
each
numbered
objection
for
which
a
hearing
is
requested
shall
include
a
detailed
description
and
analysis
of
the
specific
factual
information
intended
to
be
presented
in
support
of
the
objection
in
the
event
that
a
hearing
is
held
.
failure
to
include
such
a
description
and
analysis
for
any
particular
objection
shall
constitute
a
waiver
of
the
right
to
a
hearing
on
the
objection
.
three
copies
of
all
documents
shall
be
submitted
and
shall
be
identified
with
the
docket
number
found
in
brackets
in
the
heading
of
this
document
.
any
objections
received
in
response
to
the
regulation
may
be
seen
in
the
dockets
management
branch
between
9
am
.
and
4
pm
,
monday
through
friday
.
fda
will
publish
notice
of
the
objections
that
the
agency
has
received
or
lack
thereof
in
the
federal
register
xi
.
references
the
following
references
have
been
placed
on
display
in
the
dockets
management
branch
(
address
above
)
and
may
be
seen
by
interested
persons
between
9
am
.
and
4
pm
,
monday
through
friday
.
1
.
weisburger
,
e
.
k
.
et
al
,
`
testing
of
twentyone
twenty
one
environmental
aromatic
amines
or
derivatives
for
longterm
long
term
toxicity
or
carcinogenicity
'
journal
of
environmental
pathology
and
toxicology
,
,
2325356
,
1978
.
2
.
kokoski
,
c
.
j
,
`
regulatory
food
additive
toxicology
'
in
`
chemical
safety
regulation
and
compliance
'
edited
by
f
.
homburger
and
j
.
k
.
marquis
,
s
.
karger
,
ny
,
pp
.
2433
,
1985
.
3
.
memorandum
of
conference
of
the
cancer
assessment
committee
,
`
paratoluidine
para
toluidine
'
02/24/1981
.
4
.
report
of
the
quantitative
risk
assessment
committee
,
`
estimation
of
the
upperbound
upper
bound
lifetime
risk
from
paratoluidine
para
toluidine
in
dampc
green
no
.
5
for
uses
requested
in
cap
6c0204
,
cosmetic
,
toiletry
,
and
fragrance
association
'
september
28
,
1993
.
list
of
subjects
in
21
cfr
part
74
color
additives
,
cosmetics
,
drugs
.
therefore
,
under
the
federal
food
,
drug
,
and
cosmetic
act
and
under
authority
delegated
to
the
commissioner
of
food
and
drugs
,
21
cfr
part
74
is
amended
as
follows
:
part
74listing
of
color
additives
subject
to
certification
1
.
the
authority
citation
for
21
cfr
part
74
continues
to
read
as
follows
:
authority
:
secs
.
201
,
401
,
402
,
403
,
409
,
501
,
502
,
505
,
601
,
602
,
701
,
721
of
the
federal
food
,
drug
,
and
cosmetic
act
(
21
usc
.
321
,
341
,
342
,
343
,
348
,
351
,
352
,
355
,
361
,
362
,
371
,
379e
.
2
.
section
74
1205
is
amended
by
revising
paragraph
(
c2
)
to
read
as
follows
:
§
74
1205
dampc
green
no
.
5
.
*
*
*
*
*
*
*
*
*
*
(
c
)
*
*
*
*
*
*
(
2
)
dampc
green
no
.
5
may
be
safely
used
for
coloring
drugs
generally
,
including
drugs
intended
for
use
in
the
area
of
the
eye
,
in
amounts
consistent
with
current
good
manufacturing
practice
.
*
*
*
*
*
*
*
*
*
*
3
.
section
74
2205
is
amended
by
revising
paragraph
(
b
)
to
read
as
follows
:
§
74
2205
dampc
green
no
.
5
.
*
*
*
*
*
*
*
*
*
*
(
b
)
uses
and
restrictions
.
.
dampc
green
no
.
5
may
be
safely
used
for
coloring
cosmetics
generally
,
including
cosmetics
intended
for
use
in
the
area
of
the
eye
,
in
amounts
consistent
with
current
good
manufacturing
practice
.
*
*
*
*
*
*
*
*
*
*
dated
:
08/04/1994
.
<
supplem
>
<
signer
>
michael
r
.
taylor
,
<
signer
>
<
signjob
>
deputy
commissioner
for
policy
.
<
signjob
>
<
frfiling
>
[
fr
doc
.
9419483
filed
08/09/1994
;
845
am
]
<
frfiling
>
<
billing
>
billing
code
416001f
<
billing
>
<
text
>
